Level of an Advanced Glycated End Product Is Genetically Determined
A Study of Normal Twins
- R. David G. Leslie1,
- Huriya Beyan1,
- Pam Sawtell1,
- Bernard O. Boehm2,
- Tim D. Spector3 and
- Harold Snieder34
- 1Department of Diabetes and Metabolism, St. Bartholomew’s Hospital, London, U.K
- 2Division of Endocrinology and Diabetes, Department of Internal Medicine, University of Ulm, Ulm, Germany
- 3Twin Research & Genetic Epidemiology Unit, St. Thomas’ Hospital, London, U.K
- 4Georgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, Augusta, Georgia
- Address correspondence and reprint requests to Professor David Leslie, St. Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, U.K. E-mail: r.d.g.leslie{at}qmul.ac.uk
Abstract
Reducing sugars react with amino groups in proteins, lipids, and nucleic acids to produce advanced glycation end products (AGEs), including Nε-carboxymethyl lysine (CML), which have been implicated in oxidative stress and vascular damage. The aim of this study was to determine whether genetic factors influence serum CML levels in normal subjects. We performed a classical twin study of CML in healthy nondiabetic female twins, 39 monozygotic and 45 dizygotic pairs, aged 21–74 years. Serum CML levels were estimated by enzyme-linked immunosorbent assay. Twin correlations (r) for serum CML levels were higher in monozygotic (r = 0.71) compared with dizygotic (r = 0.50) twin pairs, suggesting a substantial genetic effect and confirmed by quantitative genetic model fitting. Additive genetic effects (heritability) explained 74% (95% CI 58–84) of population variance in CML. Heritability (%) of fasting glucose (51%) and HbA1c (62%) could not explain CML heritability, which was not associated with them. CML levels are, therefore, predominantly genetically determined and independent of genes influencing fasting glucose or HbA1c. Thus familial, largely genetic factors influence AGE implicating these glycoxidation products in the genetic contribution to macro- and microvascular disease.
Footnotes
-
- Accepted June 10, 2003.
- Received February 21, 2003.
- DIABETES














